Carla Treloar
Overview
Explore the profile of Carla Treloar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
240
Citations
2131
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Broady T, Drysdale K, Brener L, Schroeder S, Marshall A, Lafferty L, et al.
Public Health
. 2025 Mar;
242:103-110.
PMID: 40054291
Objectives: Community attitudes contribute to social exclusion of people with incarceration and injecting drug use histories. Interventions that positively impact community attitudes can strengthen efforts to reduce recidivism and support...
2.
Reilly R, McKetin R, Barzi F, Degan T, Ezard N, Conigrave K, et al.
J Med Internet Res
. 2025 Mar;
27:e58341.
PMID: 40053754
Background: Digital interventions can help to overcome barriers to care, including stigma, geographical distance, and a lack of culturally appropriate treatment options. "We Can Do This" is a web-based app...
3.
Ritter A, Bell J, Strang J, Ezard N, Rodgers C, Belackova V, et al.
Int J Drug Policy
. 2025 Mar;
138:104749.
PMID: 40037105
Supervised Injectable Opioid Treatment (SIOT) targets people experiencing opioid dependence who have not benefited from existing treatments. In this population, SIOT has been demonstrated to be efficacious and effective, yet...
4.
Nourse G, Farrugia A, Seear K, Lenton E, Cama E, Treloar C
Health (London)
. 2025 Feb;
:13634593251323000.
PMID: 39998899
Stigma related to blood-borne viruses (BBVs) and sexually transmitted infections (STIs) has been shown to undermine the quality of healthcare. Given the pervasiveness and multiple manifestations of stigma within healthcare...
5.
Gendera S, Lancaster K, Rhodes T, Treloar C
Drug Alcohol Rev
. 2025 Feb;
44(3):829-841.
PMID: 39957328
Introduction: How people connect with opioid agonist treatment is an ongoing concern. Extended-release buprenorphine depot (BUP-XR) has been designed with 'retention' in mind. It is important to consider what makes...
6.
Stevens A, Lafferty L, Treloar C, Cunningham E, Dore G, Grebely J, et al.
Int J Drug Policy
. 2025 Feb;
137:104720.
PMID: 39892268
Background: Hepatitis C (HCV) testing innovations such as dried blood spot (DBS) and point-of-care testing should have fewer client-related barriers than traditional diagnostic pathways, yet there is limited evidence on...
7.
Smith A, Brener L, Broady T, Saliba B, Keen P, Prain B, et al.
Soc Sci Med
. 2025 Jan;
367:117729.
PMID: 39889381
Patient work refers to the quotidian labour undertaken by individuals to manage health, often unrecognised by health systems. This article argues that anticipated and received stigma and inclusivity labour comprise...
8.
Chandra S, Broom A, Peterie M, Ridge D, Kenny K, Lafferty L, et al.
Qual Health Res
. 2024 Dec;
:10497323241302668.
PMID: 39680801
The stage is set for a new era of precariousness in modern medicine, driven by the increasing failure of a key pharmaceutical pillar-antimicrobials. In the context of sexually transmitted infections...
9.
Lafferty L, Applegate T, Lewis S, Drysdale K, Monaghan R, Kelly-Hanku A, et al.
BMC Infect Dis
. 2024 Nov;
24(1):1317.
PMID: 39558237
Background: There exist multiple regulatory layers for point-of-care (POC) testing to be implemented within Australia. This qualitative analysis sought to understand the pre-market barriers and facilitators to scale-up infectious diseases...
10.
Brener L, Horwitz R, Cama E, Vu H, Jin D, Wu K, et al.
BMC Public Health
. 2024 Oct;
24(1):2801.
PMID: 39396947
Introduction: Hepatitis B is a significant public health concern and a leading cause of liver cancer across the world. In Australia, hepatitis B is largely endemic in migrant communities, particularly...